These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 28622841)

  • 21. Standard and Genomic Tools for Decision Support in Breast Cancer Treatment.
    Henry NL; Bedard PL; DeMichele A
    Am Soc Clin Oncol Educ Book; 2017; 37():106-115. PubMed ID: 28561710
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population-Based Study to Determine the Health System Costs of Using the 21-Gene Assay.
    Mittmann N; Earle CC; Cheng SY; Julian JA; Rahman F; Seung SJ; Levine MN
    J Clin Oncol; 2018 Jan; 36(3):238-243. PubMed ID: 29193984
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Adjuvant!Online--an Internet-based decision tool for adjuvant chemotherapy in early breast cancer].
    Hess V
    Ther Umsch; 2008 Apr; 65(4):201-5. PubMed ID: 18622911
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and molecular aspects of breast cancer: Targets and therapies.
    Godone RLN; Leitão GM; Araújo NB; Castelletti CHM; Lima-Filho JL; Martins DBG
    Biomed Pharmacother; 2018 Oct; 106():14-34. PubMed ID: 29945114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mammaprint™: a comprehensive review.
    Brandão M; Pondé N; Piccart-Gebhart M
    Future Oncol; 2019 Jan; 15(2):207-224. PubMed ID: 30156427
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of the 21-gene assay for guiding adjuvant chemotherapy decisions in early breast cancer.
    Paulden M; Franek J; Pham B; Bedard PL; Trudeau M; Krahn M
    Value Health; 2013; 16(5):729-39. PubMed ID: 23947965
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptor-positive, human epidermal growth factor receptor 2-negative early-stage breast cancer.
    Albanell J; Svedman C; Gligorov J; Holt SD; Bertelli G; Blohmer JU; Rouzier R; Lluch A; Eiermann W
    Eur J Cancer; 2016 Oct; 66():104-13. PubMed ID: 27544930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Utility of a web-based breast cancer predictive algorithm for adjuvant chemotherapeutic decision making in a multidisciplinary oncology center.
    Epstein RJ; Leung TW; Mak J; Cheung PS
    Cancer Invest; 2006; 24(4):367-73. PubMed ID: 16777688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2-) breast cancer: When might multigene assays be of value?
    Aapro M; De Laurentiis M; Rea D; Bargallo Rocha JE; Elizalde R; Landherr L; Linderholm B; Mamounas E; Markopoulos C; Neven P; Petrovsky A; Rouzier R; Smit V; Svedman C; Schneider D; Thomssen C; Martin M
    Breast; 2017 Jun; 33():191-199. PubMed ID: 28441617
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic issues involved in integrating genomic testing into clinical care: the case of genomic testing to guide decision-making about chemotherapy for breast cancer patients.
    Marino P; Siani C; Bertucci F; Roche H; Martin AL; Viens P; Seror V
    Breast Cancer Res Treat; 2011 Sep; 129(2):401-9. PubMed ID: 21061059
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Over-using chemotherapy in the adjuvant setting.
    Curigliano G; Criscitiello C; Esposito A; Pruneri G
    Breast; 2017 Feb; 31():303-308. PubMed ID: 27866835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario.
    Levine MN; Julian JA; Bedard PL; Eisen A; Trudeau ME; Higgins B; Bordeleau L; Pritchard KI
    J Clin Oncol; 2016 Apr; 34(10):1065-71. PubMed ID: 26598746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays.
    Hyams DM; Schuur E; Angel Aristizabal J; Bargallo Rocha JE; Cabello C; Elizalde R; García-Estévez L; Gomez HL; Katz A; Nuñez De Pierro A
    J Surg Oncol; 2017 May; 115(6):647-662. PubMed ID: 28211064
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of genomics on adjuvant treatments for pre-invasive and invasive breast cancer.
    Abu-Khalf M; Pusztai L
    Breast; 2013 Aug; 22 Suppl 2():S83-7. PubMed ID: 24074799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Breast cancer and genomic testing.
    Liedtke C; Kolberg HC
    Br J Surg; 2017 Jun; 104(7):799-801. PubMed ID: 28300277
    [No Abstract]   [Full Text] [Related]  

  • 36. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
    Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
    J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjuvant early breast cancer systemic therapies according to daily used technologies.
    Jacot W; Gutowski M; Azria D; Romieu G
    Crit Rev Oncol Hematol; 2012 Jun; 82(3):361-9. PubMed ID: 22024387
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvant chemotherapy--yes or no? Prognostic markers in early breast cancer.
    Piccart-Gebhart MJ; Sotiriou C
    Ann Oncol; 2007 Dec; 18 Suppl 12():xii2-7. PubMed ID: 18083699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Accuracy of the online prognostication tools PREDICT and Adjuvant! for early-stage breast cancer patients younger than 50 years.
    Engelhardt EG; van den Broek AJ; Linn SC; Wishart GC; Rutgers EJT; van de Velde AO; Smit VTHBM; Voogd AC; Siesling S; Brinkhuis M; Seynaeve C; Westenend PJ; Stiggelbout AM; Tollenaar RAEM; van Leeuwen FE; van 't Veer LJ; Ravdin PM; Pharaoh PDP; Schmidt MK
    Eur J Cancer; 2017 Jun; 78():37-44. PubMed ID: 28412587
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical application and utility of genomic assays in early-stage breast cancer: key lessons learned to date.
    Chia SKL
    Curr Oncol; 2018 Jun; 25(Suppl 1):S125-S130. PubMed ID: 29910655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.